Clinical trials: Locally Advanced Pancreatic Carcinoma
Pancreatic Cancer
Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic Cancer
The intention of this trial is to determine the maximum tolerated of the treatment combination and to evaluate its safety and efficacy.
- Trial name
- NCT00463840
- Testing
- Oxaliplatin, 5FU, Radiation
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- NYU Langone Health
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
Stereotactic Radiosurgery and Metformin in Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer
This pilot clinical trial studies stereotactic radiosurgery and metformin hydrochloride in treating patients with pancreatic cancer that may be removed (borderline-resectable) or not removed by surgery.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage I-III Pancreatic Cancer
- Trial name
- NCT02153450
- Testing
- metformin hydrochloride, stereotactic radiosurgery
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Case Comprehensive Cancer Center
Pancreatic Cancer
Chemoradiation With Gemcitabine in Combination With Panitumumab for Patients With Locally Advanced Pancreatic Cancer
The purpose of this study is to investigate whether the addition of panitumumab to radiotherapy plus gemcitabine will increase the number of patients who are alive and progression free at 7 months.
- Trial name
- Vectibix (NCT01175733)
- Testing
- Panitumumab
- Where
- Netherlands
- Volunteers
- 18 people
- Sponsor
- Amsterdam UMC, location VUmc
Locally Advanced Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8
Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer
This phase I trial tests the safety and tolerability of olaparib in combination with durvalumab and radiation therapy in patients with pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced) and…
- Conditions
- Locally Advanced Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Unresectable Pancreatic Carcinoma
- Trial name
- NCT05411094
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 11 sites in United States, Canada
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
Evaluation of Safety of Rexin-G Gene Transfer for Advanced Pancreatic Cancer
This is a dose-seeking study that will test the safety of increasing doses of Rexin-G, given intravenously, in patients with advanced or metastatic pancreatic cancer who have failed standard chemotherapy.
- Trial name
- NCT00121745
- Testing
- Rexin-G Dose 1, Rexin-G Dose 2, Rexin-G Dose 3
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Epeius Biotechnologies
Pancreatic Cancer
Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether nitrocamptothecin is more effective than gemcitabine for pancreatic cancer.
- Trial name
- NCT00005869
- Testing
- gemcitabine hydrochloride, rubitecan
- Where
- United States
- Sponsor
- Astex Pharmaceuticals, Inc.
Pancreatic Cancer
ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer
This 2 part study will evaluate the safety and efficacy of a combination of Avastin, Tarceva and Xeloda (ATX) as second-line treatment in patients with locally advanced and/or metastatic pancreatic cancer.
- Trial name
- NCT00925769
- Testing
- bevacizumab [Avastin], capecitabine [Xeloda], erlotinib [Tarceva]
- Where
- 2 sites in Austria
- Volunteers
- 32 people
- Sponsor
- Hoffmann-La Roche
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Gemcitabine and Radiation Therapy in Treating Patients With Locally Advanced Upper Gastrointestinal Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- NCT00544193
- Testing
- gemcitabine hydrochloride, polymerase chain reaction, immunohistochemistry staining method
- Volunteers
- 16 people
- Sponsor
- City of Hope Medical Center
Pharmacokinetics, Pancreatic Cancer
Study on Umorestat Hydrogen Sulfate Capsule in Patients With Locally Advanced/Metastatic Pancreatic Cancer
Based on the tolerability, safety and pharmacokinetics phase I/II clinical trials of ulimostat hydrochloride capsules (LH011) combined with gemcitabine hydrochloride (GEM) in locally advanced/metastatic pancreatic cancer…
- Conditions
- Pharmacokinetics, Pancreatic Cancer, Gene Polymorphisms
- Trial name
- NCT05329597
- Testing
- Genotyping
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Pancreatic Cancer
Conatumumab, Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer
RATIONALE: Monoclonal antibodies, such as conatumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT01017822
- Testing
- conatumumab, capecitabine, gemcitabine hydrochloride
- Sponsor
- Radiation Therapy Oncology Group
Cancer of Pancreas
Induction Chemotherapy, FOLFIRINOX Followed With Concurrent Capecitabine and Radiation Therapy in Inoperable Locally Advanced Cancer of the Pancreas
This prospective cohort, phase II, trial is studying induction chemotherapy combination, FOLFIRINOX regimen, consisted of oxaliplatin, irinotecan, leucovorin and fluorouracil (5-FU), for 4 cycles, followed by consolidation…
- Trial name
- NCT02311439
- Testing
- FOLFIRINOX + CRT
- Where
- Egypt
- Volunteers
- 1 people
- Sponsor
- Assiut University
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC)
The purpose of this study is to determine the recommended phase 2 dose (RP2D) of the combination of lonsurf, gemcitabine and nab-paclitaxel in Pancreatic ductal adenocarcinoma (PDAC)
- Trial name
- NCT04046887
- Testing
- Lonsurf, Gemcitabine, Nab-Paclitaxel
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Patrick Joseph Loehrer Sr.
Pancreatic Cancer
MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery
RATIONALE: Biological therapies, such as MDX-010, may stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00112580
- Testing
- ipilimumab
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Bristol-Myers Squibb
Pancreatic Cancer
Quality of Life After in Situ IRE in Locally Advanced Pancreatic Cancer
A. Pancreatic cancer background In 2012, 1,172 new pancreatic cancer patients were diagnosed in Switzerland. Only 20% of the patients with newly diagnosed pancreatic cancer are candidates for surgical resection, the only…
- Trial name
- IRE Qol (NCT02926040)
- Testing
- Irreversible electroporation
- Where
- 3 sites in Switzerland
- Volunteers
- 14 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Locally Advanced Pancreatic Cancer
Pancreatic Locally Advanced Irresectable Cancer Ablation
The aim of the PELICAN trial is to investigate the survival benefit of RFA plus standard palliative chemotherapy as compared to palliative chemotherapy alone in patients with LAPC after 2 months of induction chemotherapy.
- Trial name
- PELICAN (NCT03690323)
- Testing
- Radiofrequency ablation (RFA), FOLFIRINOX, Nab-paclitaxel plus Gemcitabine
- Where
- 2 sites in Netherlands
- Volunteers
- 228 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Pancreatic Cancer
A Phase II Study of Combine Modality Therapy in Locally Advanced Pancreatic Cancer
Induction chemotherapy will be administered every 2 weeks for 6 cycles (about 3 months). Patients who have radiological evidence of progressive disease will be shifted to salvage chemotherapy.
- Trial name
- NCT00149578
- Testing
- Gemcitabine Oxaliplatin 5FU and Leucovorin
- Where
- 2 sites in Taiwan
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- National Health Research Institutes, Taiwan
Pancreatic Neoplasms
Combination With Gemcitabine in Advanced Pancreatic Cancer
Open-label, uncontrolled, Phase I/II study to evaluate safety and efficacy of BAY86-9766 plus gemcitabine in locally advanced, unresectable or metastatic pancreatic cancer.
- Trial name
- BAGPAC (NCT01251640)
- Testing
- BAY86-9766+Gemcitabine
- Where
- 23 sites in United States, Belgium and 7 more
- Volunteers
- 90 people
- Sponsor
- Bayer
Carcinoma, Pancreatic Ductal
Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02)
The purpose of the study is to evaluate a new treatment strategy for advanced pancreatic cancer disease by combining the new investigational medicinal product Atu027 with the standard chemotherapeutic gemcitabine.
- Trial name
- Atu027-I-02 (NCT01808638)
- Testing
- Atu027 & gemcitabine in lead in safety period, Atu027 & gemcitabine in treatment arm 1, Atu027 & gemcitabine in treatment arm 2
- Where
- 9 sites in Germany
- Volunteers
- 29 people
- Sponsor
- Silence Therapeutics GmbH
Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma
Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer
This phase I trial studies the side effects and best dose of nab-paclitaxel when given together with capecitabine and radiation therapy following first treatment with chemotherapy (induction therapy) in treating patients with…
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v6 and v7
- Trial name
- NCT02394535
- Testing
- Capecitabine, Laboratory Biomarker Analysis, Nab-paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- M.D. Anderson Cancer Center
Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
BBI-355 is an oral, potent, selective checkpoint kinase 1 (or CHK1) small molecule inhibitor in development as an ecDNA (extrachromosomal DNA) directed therapy (ecDTx).
- Conditions
- Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer
- Trial name
- POTENTIATE (NCT05827614)
- Testing
- BBI-355, Erlotinib, Futibatinib
- Where
- 16 sites in United States
- Volunteers
- 85 people
- Sponsor
- Boundless Bio, Inc.